An observational study in Kidney Diseases and Transplant Failure, sponsored by Hospital do Rim e Hipertensão. Recruiting at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by Hospital do Rim e Hipertensão · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Kidney Diseases with a site in Brazil — 5 open to participants now, 11 under way, 8 of them phase 3. Kidney Diseases · Brazil.
Among the 30 studies in Kidney Diseases with a site in Brazil, this one is one of 5 that started in 2023, is one of 6 observational ones, reaches primary completion later than 1 of the 10 other live ones, and was the 25th registered.
970 studies on the registry are indexed under Kidney Diseases; 185 are open to participants now.
Browse Kidney Diseases studies →5 of the 30 studies in Kidney Diseases with a site in Brazil are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Brazil, Argentina, Australia and 35 more countries
Ages 50+
Universidade Federal Fluminense · Sites in Brazil
Ages 18–65
Dimerix Bioscience Pty Ltd · Sites in Brazil, United States, Argentina and 18 more countries
Ages 12–80
Population Health Research Institute · Sites in Brazil, Argentina, Bangladesh and 22 more countries
Ages 35–70
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 131 Kidney Diseases studies recruiting now, 77 (59%) set no upper age limit and 34 (26%) stop at 75 or younger; 27 take children under 18; 22 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 14 · Phase 4 1
First in 2002; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,450 is above the median of 246 across 278 observational studies indexed under Kidney Diseases.
Median enrollment 394 across the 24 interventional studies, 1,879 across the 6 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 30 have an industry lead sponsor. The 10 most frequent:
Hospital do Rim e Hipertensão is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Hospital do Rim e Hipertensão has 1 study filed under Kidney Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Kidney Diseases with a site in Brazil that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06087835Phase 3AstraZenecaStudy to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | 2027-02-18 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Kidney Diseases with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluation of the frequency of APOL1 gene variants in kidney donors and the impact of these variants on the long-term renal function of kidney transplant donors and recipients.
Introduction: Chronic kidney disease (CKD) is a worldwide public health problem and kidney transplantation, when indicated, is the treatment of choice for CKD. Kidney transplant survival at the end of the first year is greater than 95%, however, there has not been a corresponding improvement in long-term kidney graft survival outcomes. Factors such as acute or chronic rejection, bacterial or viral infections, de novo or recurrent glomerulopathies are associated with worsening kidney function in the long term. Genetic variants of the Apolipoprotein L1 (APOL1) gene present in individuals with African ancestry (AF) may also interfere with transplant results. In the general population, individuals with SCA have a higher risk of CKD and one of the most accepted hypotheses is that the APOL1 gene is associated with CKD. Genetic variants (G1 and G2) are exclusive to individuals with SCA and confer a higher risk of CKD. In the transplant population, kidneys from deceased donors of African ancestry (AF) with genetic variants of the APOL1 gene have worse renal graft survival. Recipients with the genetic variants, regardless of donor genotype, are at increased risk of rejection and graft loss by immune-mediated mechanisms that damage the kidney through activation of T and NK cells. In Brazil, more than 5000 transplants are performed per year and it is one of the countries outside Africa with the highest number of Afro-descendants, a high rate of miscegenation and a high prevalence of African ancestry. Despite this, there are no studies on the frequency of APOL1 gene variants in this population, as well as their impact on the clinical evolution of kidney transplantation. General objective: To evaluate the association between APOL1 gene risk variants and long-term renal function in living donors and their respective recipients. Specific objectives: i - To measure the prevalence of APOL1 gene variants in the population of living kidney donors; ii - Evaluate the impact of the presence of APOL1 gene risk variants in living kidney donors, on renal graft survival in their respective recipients; iii- To verify the impact of the presence of risk variants of the APOL1 gene on the long-term renal function of living kidney donors after nephrectomy for donation. Methodology: Evaluation of recipients: longitudinal, observational, retrospective cohort study. Adult kidney transplant recipients from a living donor will be included, who have undergone the transplant at the Hospital do Rim in the period between January 1, 2008 and March 31, 2015, and who remained alive and with a functioning graft one year after the transplant. . The observation period will be until March 2020 (five years). The following will be excluded: recipients who have previously undergone transplantation of other organs and recipients who were transferred for follow-up in other centers before 12 months of follow-up after the transplant was performed. Donor evaluation: cross-sectional cohort study in donors who donated a kidney in the period between January 1, 2008 and March 31, 2015. The prevalence of APOL1 gene variants in this population will be determined and clinical information will be evaluated of the donors, from the date of the nephrectomy until the moment of collection of the exams. In the period covered, 2152 transplants were performed with a living donor. It is estimated that the prevalence of APOL1 gene variants is between 8 and 13%, including populations with chronic kidney disease and who underwent kidney transplantation. To calculate the sample number, it will be assumed, by hypothesis, to find a difference of 10 ml/min/1.73m2 in the mean Estimated Glomerular Filtration Rate (eGFR) at the end of 5 years between recipients of kidneys from donors who present some risk mutation (recessive model) compared with those who do not have any risk mutation. To prove this average in the eGFR, the minimum number required is 98 individuals in each group. It will be assumed that the minimum frequency of mutations is 8% in the population of interest, to reach 98 individuals in each group, the total number of individuals required to be evaluated for the presence of mutation will be 1225 donors. Considering that there will be a loss of follow-up of 20% of the total number of individuals, the total number of donors required to be invited will be 1,535 patients. By including 1,225 donors, 1,225 recipients will be included, totaling 2,450 individuals. Primary endpoint: eGFR 5 years after transplantation in recipients. Secondary endpoints: eGFR decay rate between 1 and 5 years after kidney transplantation in recipients; Graft loss in up to 5 years of follow-up; Death in recipients within 5 years of follow-up; Acute rejection. Exploratory outcomes: current eGFR in donors.
1.1.2.For evaluation of living donor kidney transplant recipients It will be a longitudinal, observational, retrospective cohort study. Adult kidney transplant recipients from a living donor will be included, who have performed the transplant at the Hospital do Rim in the period between January 1, 2008 and March 31, 2015, who remained alive and with a functioning graft one year after the transplant. The observation time will be until March 2020, so that all recipients have had the opportunity to complete at least 5 years of follow-up after transplantation.
Inclusion Criteria:
1.1.1.1. Inclusion criteria 1.1.1.2. For recipients:
For donors:
Exclusion Criteria:
For recipients:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For evaluation of living donor kidney transplant recipients
It will be a longitudinal, observational, retrospective cohort study. Adult kidney transplant recipients from a living donor will be included, who have performed the transplant at the Hospital do Rim in the period between January 1, 2008 and March 31, 2015, who remained alive and with a functioning graft one year after the transplant. The observation time will be until March 2020, so that all recipients have had the opportunity to complete at least 5 years of follow-up after transplantation
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Oct 2024, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital do Rim e Hipertensão